Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) is an enzyme that is produced by inflammatory cells (macrophages, T-lymphocytes and mast cells) and hydrolyzes oxidized phospholipids in LDL. Several epidemiology studies indicate that Lp-PLA 2 appears to be an independent marker of cardiovascular risk. This study was conducted to define the distribution of Lp-PLA 2 in a large population-based cohort and to determine associations between Lp-PLA 2 and other risk factors for CVD. The study group consisted of participants from the Malmö Diet and Cancer study (1992)(1993)(1994). LpPLA 2 (activity and mass) was measured from samples obtained at baseline for 5,402 participants (3,167 women). A strong correlation was observed between LpPLA 2 activity and mass in this study (r=0.57). Highest correlations were observed between Lp-PLA 2 activity and LDL (r=0.45) and LDL/HDL ratio (r=0.54) and a strong inverse correlation to HDL (r=-0.31). The correlations between Lp-PLA 2 mass and lipids were not as strong as the correlation between activity and lipids.
INTRODUCTION
Intensive research efforts have been underway for the past decade to improve the understanding of vascular biology and the pathogenesis of atherosclerosis and atherothrombosis, which are the underlying culprits associated with myocardial infarction, stroke, and other occlusive vascular diseases. One of the great achievements of these efforts is the recognition of atherosclerosis as an inflammatory disease. Inflammation is present at every stage of atherosclerosis-initiation, progression, and destabilization of atheroma-and mechanistic studies have identified blood-borne inflammatory cells and their products as primary drivers of the inflammatory processes (1, 2) . With this information, several epidemiologic studies were initiated to explore components of the inflammatory processes and their association with acute cardiovascular events. Examples of inflammatory risk markers that have been studied include interleukin-1, interleukin-6, tumor necrosis factor, interferon-, serum amyloid A, leukocyte count, fibrinogen, and C-reactive protein (CRP), and the list is growing (1, 3).
Lipoprotein-associated phospholipase A 2 is a novel inflammatory marker that been studied for a potential association with cardiovascular events. The biology of this enzyme in atherosclerosis has been controversial, with initial studies suggesting an atheroprotective effect through its actions in hydrolyzing polar phosphatidylcholines (particularly plateletactivating factor) (4) (5) (6) . However, more recent reports suggest the actions of Lp-PLA 2 are proatherogenic (7) . In humans, Lp-PLA 2 in circulation is bound predominantly to LDL (8) , and oxidative modification to the phospholipid component of LDL provides the substrate for 4 the enzyme (9, 10) . Lp-PLA 2 acts very rapidly following LDL oxidation to hydrolyze one of the fatty acid moieties (sn-2) of the phospholipid to produce two inflammatory moleculesoxidized nonesterified fatty acids and lysophosphatidylcholine (lysoPC) (7) . Given that the majority of total body oxidized LDL resides within the intima (versus in circulation), the products of Lp-PLA 2 activity are generated within the vessel wall where the inflammatory processes of atherosclerosis occur. Both oxidized nonesterified fatty acids and lysoPC are highly soluble, diffuse throughout atheroma, and affect the various cell types involved in atherosclerosis (9) .
Recent epidemiology studies have examined the role of Lp-PLA 2 in predicting incident cardiovascular events (11) (12) (13) (14) (15) . The majority of these studies have demonstrated that elevated Lp-PLA 2 (mass or activity) is an independent predictor of future events. There is also emerging evidence that elevated Lp-PLA 2 may confer increased risk for recurrent events in patients with clinically manifested CVD (ie, recurrent events in secondary prevention populations) (16, 17) .
However, an extensive examination of the associations of demographic and anthropometric characteristics and other CVD risk factors with plasma Lp-PLA 2 has not been well described in a large, population-based cohort. Therefore, the purpose of this study was to examine the cross-sectional associations of Lp-PLA 2 within the Cardiovascular Cohort of the Malmö Diet and Cancer Study.
METHODS

Subjects
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The Malmö Diet and Cancer Study is a population-based prospective cohort study designed to explore the associations between dietary habits and cancer (18) . All men and women aged 45-69 years living in the city of Malmö, Sweden was eligible for participation and 28,098 individuals were enrolled in the study. At baseline, anthropometry, blood pressure, hereditary, dietary, socioeconomic, and life style factors were determined and whole blood samples were obtained. Between November 1991 and February 1994, every other participant was randomly invited to participate in a sub-study exploring the associations between cardiovascular risk factors and ultrasound-determined degree of atherosclerosis, hereto known as the Cardiovascular Cohort. This cohort consisted of 6,103 subjects (3,531 women and 2,572 men) and has previously been described in detail (19) . Age at baseline examination was between 46 and 68 years of age (mean 58 years). Fasting blood samples were not collected at the baseline visit due to practical reasons. Participants instead were asked to return for a subsequent visit (median time of 8.6 months after the baseline visit) to donate whole blood samples in a fasting state. A total 5,540 of the 6,103 subjects returned to donate samples. Of these participants, sufficient stores of plasma were available from 5,402 (3,167 women and 2,235 men) for the purpose of measuring Lp-PLA 2 . In the present study demographic and baseline characteristics of the participants providing the 5,402 samples were nearly identical to the Cardiovascular Cohort as a whole (data not shown).
Measurements
At the baseline examination, each subject was seen by a nurse for anthropometrics, supine blood pressure measurement, non-fasting blood sampling and administration of questionnaires 6 including hereditary, medical condition, dietary, socioeconomic and life style factors. During this visit, ultrasound examination of the right carotid artery was performed. The carotid bifurcation was imaged for the existence of atherosclerotic plaque, defined as focal thickening of the intima-media layer. Intima-media thickness was determined in the far wall of the distal common carotid artery (IMT cca) and in carotid bifurcation (IMT bulb), according to the leading edge principle and using a specially designed computer-assisted image analysis system (20) . The examination procedure and image analysis was performed by specially trained and certified sonographers Plaque score (values of 0, 1, or 2) was constructed in which 0 corresponded to no visual plaque, 1 corresponded to a visual plaque less than 10 mm² and 2 corresponded to ≥10mm². Plaque occurrence was defined as a focal thickening of intima-media wall more than 1.25mm.
Diabetes mellitus was defined as self-reported physician-diagnosis per questionnaire and current diabetic treatment. Smoking habits were classified as current smoker, ex-smoker and never smoker. Education was obtained from the questionnaire and classified into one of three groups-9 years or less, 9 to 12 years, or more than 12 years of formal education. In some analyses, a 2 grade scale was used for classifying education, which included 10 years or less or more than 10 years of formal education. Physical activity was calculated from questions adapted from the Minnesota Leisure Time Physical Activity Questionnaire including 18 different physical activities, separately for the four seasons. The number of minutes per week of each activity was multiplied with an intensity coefficient (21) . Blood pressure was 
Measurement of LpPLA 2 mass and activity
Plasma aliquots prepared from fasted blood samples were collected and stored at -80°C. Lp-PLA 2 activity was measured using [3H] PAF (platelet activating factor) as substrate using methodology described previously (15). Briefly, plasma (5uL) or assay buffer (for determination of background and total dpm) were transferred into a 96 well flat-bottomed polystyrene plate (Costar) and allowed to equilibrate to room temperature. A 100uL aliquot of and LpPLA 2 activity values (nmol PAF hydrolysed/min/mL) were derived from the raw data.
Lp-PLA 2 mass measurements were performed using the PLAC™ Test (diaDexus Inc., South San Francisco, CA, USA). In brief, the test resembles a sandwich enzyme immunoassay with two specific monoclonal antibodies as described by Caslake et al (24) combined with a horseradish-peroxidase (HRP) -tetramethylbenzidine (TMB) detection system. The change in absorbance resulting from the enzymatic turnover of the substrate was measured spectrophotometrically (Wallac, now Perkin Elmer Inc, Boston, MA, USA) and is directly proportional to the concentration of Lp-PLA 2 present in the study sample. A 6-point standard curve with known Lp-PLA 2 quantities, provided by the manufacturer, was employed to determine Lp-PLA 2 concentration from the study samples. All samples were analyzed in duplicates and a duplicate was expected to show a coefficient of variation of less than 20 percent.
Statistical Methods
The distributions of triglycerides, glucose, insulin, HOMA, HbA 1 C, hsCRP and physical activity were markedly skewed and therefore were log-transformed. Means (medians for skewed variables) and percentages for baseline demographic and clinical characteristics were computed for the entire cohort and by sex. For continuous factors, we assessed correlation of Lp-PLA 2 with variables three ways with use of Pearson's or Spearman's correlation coefficient: partially adjusted for age and sex, partially adjusted for age, sex and LDL-level, and partially adjusted for age, stratified by sex. Further, we divided continuous factors into tertiles and computed mean Lp-PLA 2 level within each tertile, stratified by sex. Mean Lp-PLA 2 was computed and adjusted for age and sex by analysis of covariance for key categorical risk factors. Differences between categories were calculated and expressed with 95% confidence intervals. A general linear model was used to examine the incremental influence (cumulative R 2 ) of risk factors for the degree of explanation of the variation in Lp-PLA 2 . All other analyses were performed using SPSS 11.0.
RESULTS
The baseline demographics of the Cardiovascular Cohort are listed in Table 1 . Fifty-nine percent of participants were women and participants were between 46 and 68 years of age (mean 58). There was a low prevalence of CV events at baseline (4 percent). LDL levels were high (mean 4.2 mmol/L (161 mg/dL)) and HDL levels were moderately high (mean 1.4 mmol/L (54 mg/dL)), as is common in other northern European populations. Of the participants who self-reported having diabetes, hypertension, or hypercholesterolemia, 1.6 percent, 13 percent, and 2.4 percent, respectively, received pharmacologic therapy at baseline.
Fourteen percent of women participating in this study were receiving hormone replacement therapy at baseline.
The distributions of Lp-PLA 2 activity and mass in the study population were approximately normal with a slight right skewness ( Figures 1A and 1B) . Mean (SD) Lp-PLA 2 activity was 45.5 (13.1) nmol/min/mL; mean Lp-PLA 2 mass was 269.8 (80.7) ng/mL. The correlation between Lp-PLA 2 activity and mass was r=0.57 (p<.0001), with a tendency toward greater variability at higher levels ( Figure 2 ).
Associations between LpPLA 2 Activity/ Mass and Cardiovascular Risk Factors
The correlations between Lp-PLA 2 activity and mass and cardiovascular risk factors are listed in Table 2 and Table 3A , 3B. Lp-PLA 2 activity was positively associated with age (r=0.11;
p<0.0001) ( Table 2 ) a correlation that was stronger in women (r=0.15) (Table 3A ) than in men (r=0.06) (Table 3B) . However, in an LDL-adjusted model, the association between Lp-PLA 2 and age was approximately r=0.03, which suggests that the association is dependent on age-related changes in LDL. Both Lp-PLA 2 activity and mass were significantly higher in men than in women (49.6 ± 13.3 versus 42.5 ± 12.0 nmol/min/ml; p<0.0001 and 287.7 versus 257.2 ng/mL; p<0.0001); therefore, the description and associations with other cardiovascular risk factors were analyzed separately by sex.
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Of note, Lp-PLA 2 activity was not correlated with hsCRP in either men or women. Plasma
Lp-PLA 2 activity increased with a greater extent of ultrasound-determined atherosclerosis.
For women, Lp-PLA 2 activity was approximately 41 nmol/min/mL in the lowest tertile of IMT in the common carotid artery or bulb, 42 nmol/min/mL in the second tertile and 44
nmol/min/mL in the highest tertile. There was a monotonic increase in mean Lp-PLA 2 activity values across plaque score, with mean Lp-PLA 2 activity of 41 nmol/min/mL, 43 nmol/min/mL, and 45 nmol/min/mL among participants with a plaque score of 0, 1 or 2, respectively. A similar pattern of IMT, plaque score and Lp-PLA 2 was observed for men (Table 3A and 3B). Lp-PLA 2 mass also increased with a greater extent of ultrasounddetermined atherosclerosis with almost the same pattern as Lp-PLA 2 activity (data not shown).
Lp-PLA 2 Activity in Clinical Subgroups
After adjusting for age and sex, current smokers had significantly higher Lp-PLA 2 activity compared with non-smokers, and enzyme activity also was higher in participants with plaque (Table 4) . Participants with more years of formal education had significantly lower Lp-PLA 2 activity compared to those with less education. Mean Lp-PLA 2 activity was higher among the 216 participants with a history of CVD (heart disease or stroke) compared to those without prevalent CVD (48 vs. 45 nmol/min/mL; p=0.006) but this difference was eliminated after accounting for age and gender. Lp-PLA 2 activity was higher among participants with compared to without diabetes and higher among obese compared to non-obese participants, but the differences were not statistically significant. There was only marginal difference in Lp-PLA 2 activity between hypertensives and normotensives. The findings for Lp-PLA 2 mass are similar to those for Lp-PLA 2 activity with significant higher mass levels among smokers compared to non-smokers, in participants with plaque and in those with lower education (data not shown).
Lp-PLA 2 Variability
To assess how completely known CV risk factors explain the overall variability of Lp-PLA 2 , parameters were fit in a generalized linear model and the R 2 was calculated. (11) and MONICA (14) . These differences could be explained, in part, by gender composition in the different study populations, with WOSCOP and MONICA comprised entirely of male participants and in the restricted LDL range in WOSCOP. It is noteworthy that Lp-PLA 2 mass but not activity appears to be weakly correlated with hsCRP. This bears further elucidation. The lack of correlation between Lp-PLA 2 activity and hsCRP is consistent with other studies (11) (12) (13) (14) , suggesting that the two risk markers may have an additive effect on predicting cardiovascular risk for individual patients.
In at least one study, a strong correlation between enzyme mass and activity has been reported (r≥0.8) (26) , but the observed correlation was much lower in the present study (r=0.57). The stronger degree of explanation from the measured variables on Lp-PLA 2 activity than mass might indicate that activity is more closely linked to the mechanisms that ultimately lead to atherosclerosis and atherothrombosis. Alternatively, the discrepancy could be due to differences in the methodology for measuring Lp-PLA 2 activity and mass. Future studies should try to identify the factors (eg genetic, biomolecular, or assay) that could explain discrepancies between mass and activity measurements, especially at higher values ( Figure 2 ).
Another intriguing finding is that, after adjusting for age and gender, a weak correlation was observed between Lp-PLA 2 and cardiovascular risk factors associated with an excessive inflammatory burden. For example, a correlation was observed between certain markers of Type 2 diabetes (eg, insulin, HOMA, and glucose, but not HbA 1c ) in both men and women.
Body mass index was correlated with Lp-PLA 2 in men, but such a correlation was not observed in WOSCOP (11) or MONICA (14) , studies that included only men. A relationship between Lp-PLA 2 and body mass index was not apparent in women in the present study.
Smoking-which is also associated with excessive inflammatory burden-also was positively correlated with Lp-PLA 2 activity. These data are confirmed by findings from the ARIC study (13) but not by the WOSCOP (11), MONICA (14) or Rotterdam (15) studies.
Whether the oxidative stress associated with diabetes and smoking is directly attributable, in part, to Lp-PLA 2 activity is not known. In a recent study involving an animal model of diabetes and hypercholesterolemia, the expression of Lp-PLA 2 by bone-marrow derived leukocytes was significantly up-regulated in the presence of advanced glycation endproducts (27) . However, the contribution of components of the metabolic syndrome to the variation in Lp-PLA 2 needs to be explored further. Our findings with continuous parameters of metabolic disorders are compatible with an impact of deteriorated glucose metabolism increasing the level of the Lp-PLA 2 enzyme activity. However, in our study, participants with diabetes did not markedly differ in their Lp-PLA 2 levels from participants without diabetes, possibly due to how we defined diabetics as self-reported physician-diagnosis (questionnaire) and currently receiving treatment, which may be a conservative definition. Thus, additional studies are needed to explore associations with metabolic disorders.
In the present study, both plasma Lp-PLA 2 activity and mass was correlated with the extent of carotid artery atherosclerosis. This was also observed in the CARDIA study in which plaque burden was measured by electron-beam computer topography coronary artery calcification (28) . Although a causal relationship between enzyme activity and atherosclerosis is not possible to establish in this cross-sectional study, it is conceivable that Lp-PLA 2 activity is involved in the very complex processes leading to atherosclerosis and atherothrombosis. In the present study, the measured variables could only explain 35 percent of the variation in plasma Lp-PLA 2 activity and only 19 percent in plasma Lp-PLA 2 mass, suggesting that Lp-PLA 2 may be linked to atherosclerosis and cardiovascular events by different pathophysiologic mechanisms than with conventional cardiovascular risk factors. However, as mentioned above, the putative proatherogenic effects of Lp-PLA 2 are the result of enzyme activity within the intima and not within plasma.
From an epidemiologic viewpoint, this study has several advantages-it is a large, crosssectional cohort comprising 5,402 apparently healthy men and women with a homogeny ethnic composition. Other studies measuring Lp-PLA 2 have included fewer subjects or have used a nested case-control or case-cohort design for the purpose of evaluating whether Lp-PLA 2 could predict incident cardiovascular events. In the present study we have measured both Lp-PLA 2 activity and mass, which gives a broader basis for understanding how Lp-PLA 2 interacts with other cardiovascular risk factors. Subjects with diabetes, hypertension, or prevalent cardiovascular disease participated in this study, including those treated with statins, antihypertensive drugs and diuretics.
The primary limitation of this study is that the attendance rate that was only 41 percent, and the study participants were healthier and were at substantially lower risk compared with nonparticipants (29, 30) . Patients were identified as having hypertension and diabetes through self-reporting (ie, questionnaires) and description of current medications. Blood glucose and blood pressure were obtained at only one visit. However these shortcomings tend to decrease the associations studied.
In conclusion, Lp-PLA 2 is a novel cardiovascular risk marker that is correlated with other factors associated with an increased risk for cardiovascular events, particularly LDL. a) 1= never, 2= former, 3= current smoker b) 1= < 9 year 2= 9-12 year, 3= > 12 year education c) 0= no visual plaque, 1= plaque less than 10mm², 2= >10mm² a) 1= never, 2= former, 3= current smoker b) 1= < 9 year 2= 9-12 year, 3= > 12 year education c) 0= no visual plaque, 1= plaque less than 10mm², 2= >10mm² 
